Comment on the comparison of oral propranolol, oral rifampicin, and intravitreal anti-VEGF in central serous chorioretinopathy
Indian Journal of Ophthalmology · 2024
DOI: 10.4103/ijo.ijo_2774_23 ↗Kurz gefasst
Leserbrief in der Zeitschrift Indian Journal of Ophthalmology, 2024. Verfasst von Pradeep K Panigrahi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Institute of Medical Sciences and SUM Hospital, Siksha 'O' Anusandhan (Deemed to be) University, Bhubaneswar, Odisha, In…. Hauptthemen laut MEDLINE: Intravitreal Injections, Rifampin, Central Serous Chorioretinopathy, Vascular Endothelial Growth Factor A. Die Arbeit nennt 1 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Dear Editor, We went through the article titled “Comparison of oral propranolol, oral rifampicin, and intravitreal anti-VEGF in central serous chorioretinopathy” by Sandeep K et al.[1] We have some queries for the authors. The authors should have mentioned that only patients with acute central serous chorioretinopathy (CSCR) were included in the study. In addition, the average duration of symptoms before treatment is not mentioned. The average duration of symptoms should be similar in all three groups for them to be comparable. The authors noted that patients in the intravitreal group had complete fluid resolution by the end of the first month. It will be interesting to know if there was a complete resolution in all patients who received intravitreal bevacizumab by the end of the first month. The authors have mentioned that patients receiving oral rifampicin and propranolol had slower resolution of the subretinal fluid over 3 months. However, these patients were treated for a period of 1 month only. It seems illogical to stop the treatment if the fluid persists at the end of 1 month. If the treatment was only given for 1 month, then the slow resolution of subretinal fluid over the next few months cannot be attributed to the previous treatment given. It must have happened independently as a natural course of the disease process. The authors have expressed visual acuity in Snellen’s form. For the visual acuity to be quantifiable, it must be converted to decimal or logarithm of the minimum angle of resolution (logMAR) forms. The authors have mentioned that statistically significant results were obtained in their study. However, the statistical tests performed must be mentioned to arrive at such a conclusion. There is no mention of the P values anywhere in the manuscript. The patients were followed up at 4 weeks, 6 weeks, and 3 months. It is difficult to understand the logic behind having a follow-up just 2 weeks after the first post-treatment visit. Ideally, the follow-up schedule should be 1, 2, and 3 months following the initial treatment. The study period was 12 months. It will be informative to know if any patients had a recurrence during the study period. Financial support and sponsorship: Nil. Conflicts of interest: There are no conflicts of interest.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Institute of Medical Sciences and SUM Hospital, Siksha 'O' Anusandhan (Deemed to be) University, Bhubaneswar, Odisha, India.
Zitieren
APA
Panigrahi, P. K., Minj, A., & Satapathy, J. (2024). Comment on the comparison of oral propranolol, oral rifampicin, and intravitreal anti-VEGF in central serous chorioretinopathy. Indian Journal of Ophthalmology. https://doi.org/10.4103/ijo.ijo_2774_23
Vancouver
Panigrahi PK, Minj A, Satapathy J. Comment on the comparison of oral propranolol, oral rifampicin, and intravitreal anti-VEGF in central serous chorioretinopathy. Indian Journal of Ophthalmology. 2024. doi:10.4103/ijo.ijo_2774_23
BibTeX
@article{Panigrahi2024,
author = {Panigrahi, Pradeep K and Minj, Anita and Satapathy, Jasmita},
title = {Comment on the comparison of oral propranolol, oral rifampicin, and intravitreal anti-VEGF in central serous chorioretinopathy},
journal = {Indian Journal of Ophthalmology},
year = {2024},
doi = {10.4103/ijo.ijo_2774_23}
}
EUVIMED